AI Financial (AIFC) risk factors, FY2025 10-K

AI Financial's FY2025 10-K, filed Apr 13, 2026, lists 36 risk factors in 8 groups. Against the prior year's 41: 21 new, 26 dropped, 14 substantially reworded.

Open AIFC in Gloom →
AI Financial's chart, financials and news, free in your browser.Open AIFC in Gloom →
Risk factors listed
368 groups
New this year
21vs 41 last year
Dropped
26since the prior 10-K
Substantially reworded
14of those kept
Section length
8k wordsItem 1A

What the changes say

  • Company is expanding its digital asset and payment processing footprint while increasing focus on regulatory compliance, international operations, and cyber security.

What changed since the prior 10-K

New

  • NewRisks Relating to Our Business Generally

    Adverse economic conditions and volatility in crypto asset markets could reduce transaction volumes, customer activity, and access to banking and capital, which could adversely affect our business

    Adverse economic conditions and crypto market volatility could reduce transaction volumes, customer activity, and banking access.

  • NewRisks Relating to Our Business Generally

    Our operations in multiple foreign jurisdictions expose us to political, regulatory, legal, and currency risks that could adversely affect our business

    Foreign operations in Lithuania, the Czech Republic, Canada, and Saint Vincent expose the company to local regulations, currency controls, and tax risks.

  • NewRisks Relating to Our Fintech Segment

    The loss or destruction of private keys required to access our digital assets or those of our customers could result in permanent, irrecoverable loss

    The loss or theft of private keys required to access digital assets could result in permanent, irrecoverable losses.

  • NewRisks Relating to Our Fintech Segment

    The potential classification of certain crypto assets as securities by the SEC or other regulators could materially impact our business operations and require significant restructuring

    If regulators classify supported crypto assets as securities, the company could face registration requirements, fines, and restructuring.

  • NewRisks Relating to Our Fintech Segment

    Evolving tax treatment of digital assets creates uncertainty in our tax obligations and potential retroactive liabilities

    Evolving digital asset tax guidance from the IRS and international authorities creates uncertainty and potential retroactive tax liabilities.

  • NewRisks Relating to Our Fintech Segment

    We are exposed to risks from blockchain forks and from the decentralized and open-source nature of blockchain protocols, which could disrupt our platform operations, compromise network integrity, and create uncertainty regarding supported digital assets

    Blockchain network forks can create duplicate assets, disrupt trading, and require significant engineering and compliance resources.

  • NewRisks Relating to Our Fintech Segment

    Our platform is exposed to chargeback, fraud, and unauthorized transaction losses, particularly in connection with our payment card and fiat-linked services

    Payment card and fiat-linked services, including Mswipe operations from Fortress II Holdings, expose the platform to chargebacks and fraud.

  • NewRisks Relating to Our Fintech Segment

    Customer crypto assets held on our platform are not insured by the FDIC or SIPC, and customers could suffer losses in the event of platform failure

    Customer crypto assets are not insured by the FDIC or SIPC, risking total loss upon platform failure or insolvency.

  • NewRisks Relating to Our Fintech Segment

    Our banking and financial institution relationships may be disrupted, which could have a material adverse effect on our ability to operate

    Banking partners may limit or terminate relationships with crypto companies like ALT5 Sigma Canada, disrupting fiat currency processing.

  • NewRisks Relating to Our Fintech Segment

    Regulatory, investor and market focus on climate-related risks and the environmental impact of digital asset networks may impose additional compliance costs and reputational risks on our business

    Climate-related regulations and energy usage concerns around digital asset networks could impose compliance costs and reputational risks.

  • NewRisks Relating to Our Fintech Segment

    We face intense competition from larger crypto platforms, decentralized networks, traditional financial institutions and payment providers, which could reduce our market share, compress margins and increase customer acquisition costs

    Competition from larger platforms like Coinbase, Kraken, and Binance, as well as decentralized exchanges, could compress margins.

  • NewRisks Relating to Our Fintech Segment

    We are subject to risks associated with our compliance and risk management methods

    Compliance and risk management controls may fail to keep pace with transaction volume and extreme market movements.

  • NewRisks Relating to Our Fintech Segment

    We obtain, process, and store a large amount of sensitive personal and financial data and are subject to evolving data privacy, data protection, and information security laws and regulations, and any failure to protect such data or comply with applicable requirements could adversely affect our business

  • NewRisks Relating to Our Fintech Segment

    Our acquisition of Fortress II Holdings and its Mswipe payment card operations exposes us to integration, compliance, and operational risks specific to the payments industry

  • NewRisks Relating to Our Biotechnology Segment

    We may be unable to effectuate the planned formal separation of our biotechnology segment, which could adversely affect our financial condition and strategic objectives

  • NewRisks Relating to Our Biotechnology Segment

    Effectuating a formal separation of our biotechnology segment is complex and may divert management’s attention and consume significant resources, which could adversely affect both the biotechnology segment and our remaining operations

  • NewRisks Relating to Our Biotechnology Segment

    The biotechnology segment, if formally separated, may be unable to raise sufficient capital to fund its operations and development programs as a standalone entity, which could impair its viability and the value realized by our stockholders

  • NewRisks Relating to Our Biotechnology Segment

    If effectuating the formal separation results in Alyea becoming a stand-alone publicly traded entity, it may not qualify for or maintain a listing on a national securities exchange, which could impair the liquidity and value of its securities owned by us or, prospectively, by our stockholders

  • NewRisks Relating to Our Biotechnology Segment

    Effectuating the formal separation of the biotechnology segment in a spinoff transaction may have adverse tax consequences for our stockholders and for us

  • NewRisks Relating to Our Biotechnology Segment

    Unlike currently, following a formal separation of our biotechnology segment, it will operate without our financial support and may face challenges in establishing itself as a fully independent company

  • NewRisks Relating to Ownership of Our Common Stock

    Sales or distribution of substantial amounts of our Common Stock, or the perception that such sales or distributions might occur, could cause the market price of our Common Stock to decline

Dropped

  • DroppedRisks Relating to Our Business Generally

    Adverse economic conditions could adversely affect our business

  • DroppedRisks Relating to our Fintech Segment

    If we do not effectively manage our growth, including by maintaining and improving our systems and processes, our business, operating results, and financial condition could be adversely affected

  • DroppedRisks Relating to our Fintech Segment

    Due to our limited fintech operating history, it may be difficult to evaluate our business and future prospects, and we may not be able to achieve or maintain profitability in any given period

    General economic downturns causing credit restrictions and lower consumption.

  • DroppedRisks Relating to our Fintech Segment

    Any acquisitions and investments that we make could require significant management attention, disrupt our business, result in dilution to our stockholders, and could adversely affect our business, operating results, and financial condition

  • DroppedRisks Relating to our Fintech Segment

    If we fail to develop, maintain, and enhance our brand and reputation, our business, operating results, and financial condition could be adversely affected

  • DroppedRisks Relating to our Fintech Segment

    Internal key business metrics and other estimates are subject to inherent challenges in measurement and change as our business evolves, and our business, operating results, and financial condition could be adversely affected by real or perceived inaccuracies in those metrics or any changes in metrics we disclose

  • DroppedRisks Relating to our Fintech Segment

    Our platform may be exploited to facilitate illegal activity such as fraud, money laundering, gambling, tax evasion, and scams. If our platform is used to further such illegal activities, our business, operating results, and financial condition could be adversely affected

  • DroppedRisks Relating to our Fintech Segment

    Our compliance and risk management methods might not be effective and may result in outcomes that could adversely affect our reputation, operating results, and financial condition

  • DroppedRisks Relating to our Fintech Segment

    We obtain and process a large amount of sensitive customer data. Any real or perceived improper use of, disclosure of, or access to such data could harm our reputation, as well as adversely affect our business, operating results, and financial condition

  • DroppedRisks Relating to our Fintech Segment

    assurance that our intellectual property rights will be sufficient to protect against others offering products, services, or technologies that are substantially similar to ours and that compete with our business

  • DroppedRisks Relating to Our Biotechnology Segment

    If we fail to implement our biopharmaceutical business strategy or if our biopharmaceutical business strategy is ineffective, our financial performance could be materially and adversely affected

  • DroppedRisks Relating to Our Biotechnology Segment

    Our biotechnology business has a limited operating history

    Managing growth and scaling systems and processes.

  • DroppedRisks Relating to Our Biotechnology Segment

    Our business model is partially dependent on certain patent rights licensed to us from the Licensors (as defined below), and the loss of those license rights would, in all likelihood, cause our business, as presently contemplated, to fail

    Limited fintech operating history since acquiring the crypto processing segment in 2024.

  • DroppedRisks Relating to Our Biotechnology Segment

    Pharmacies may be able to compound LDN in competition with us, but the economic impact may not be material

    Risks related to acquisitions, joint ventures, and strategic investments.

  • DroppedRisks Relating to Our Biotechnology Segment

    If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our initial or subsequent product candidates

    Developing, maintaining, and defending the ALT5 brand.

  • DroppedRisks Relating to Our Biotechnology Segment

    The success of our biotechnology business is entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory authorities in foreign jurisdictions in which we intend to market them, of which there can be no assurance

    Inaccuracies or changes in internal key business metrics.

  • DroppedRisks Relating to Our Biotechnology Segment

    of the FDA’s 505(b)(2) regulatory pathway, we will be required to conduct Phase IIb and Phase III studies prior to filing for marketing approval of JAN101

    Platform exploitation for illegal activities like gambling and tax evasion.

  • DroppedRisks Relating to Our Biotechnology Segment

    Clinical testing is expensive, is difficult to design and implement, can take many years to complete, and is uncertain as to outcome

    Ineffective compliance and risk management methods.

  • DroppedRisks Relating to Our Biotechnology Segment

    Even if we receive regulatory approval for JAN101 or JAN123, we may not be able to commercialize it successfully and the revenue that we generate from its sales, if any, may be limited

    Improper use or disclosure of sensitive customer personal data.

  • DroppedRisks Relating to Our Biotechnology Segment

    Obtaining and maintaining regulatory approval of JAN101 or JAN123 in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of JAN101 or JAN123 in other jurisdictions

  • DroppedRisks Relating to Our Biotechnology Segment

    Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our initial or subsequent product candidates and affect the prices we may obtain

    Insufficient intellectual property protection.

  • DroppedRisks Relating to Our Biotechnology Segment

    Any termination or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidate for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects

  • DroppedRisks Relating to Our Biotechnology Segment

    Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues

  • DroppedRisks Relating to Our Biotechnology Segment

    It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights

    Implementation of the biopharmaceutical business strategy.

  • DroppedRisks Relating to Our Biotechnology Segment

    It is difficult and costly to block others from developing similar products for other indications, and we cannot ensure that these products will not be less expensive and thus be prescribed off-label by physicians for use in our indications

    Limited operating history of the biotechnology business and JAN101/JAN123 products.

  • DroppedRisks Relating to Our Biotechnology Segment

    JAN101 or JAN123 may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts

Reworded

  • 88% rewrittenRisks Relating to Our Fintech Segment

    If we fail to retain existing customers or add new customers, or if our customers decrease their level of engagement with our products, services and platform, our business, operating results, and financial condition may be significantly harmed

    Added specific mention of increased competition from decentralized exchanges, noncustodial platforms, and traditional financial institutions.

  • 76% rewrittenRisks Relating to Our Fintech Segment

    We are subject to an extensive, highly-evolving, and uncertain regulatory landscape and any adverse changes to, or our failure to comply with, any laws and regulations could adversely affect our brand, reputation, business, operating results, and financial condition

    Removed federal government contractors from the list of regulatory domains.

  • 70% rewrittenRisks Relating to Our Fintech Segment

    Any significant disruption in our products and services, in our information technology systems, or in any of the blockchain networks we support, could result in a loss of customers or funds and adversely affect our brand, reputation, business, operating results, and financial condition

    Expanded third-party service provider risks to explicitly list natural disasters, cyberattacks, insider threats, and geopolitical conflicts.

  • 68% rewrittenRisks Relating to Our Fintech Segment

    Cyberattacks and security breaches of our platform, or those impacting our customers or third parties, could adversely affect our brand, reputation, business, operating results, and financial condition

    Reformatted bullet points regarding security breaches and remediation costs into standard sentence structure.

  • 64% rewrittenRisks Relating to Our Business Generally

    If our estimates or judgment relating to our critical accounting estimates prove to be incorrect, our operating results could be adversely affected

    Added specific critical accounting estimates including business combinations, goodwill, revenue recognition, and digital assets.

  • 63% rewrittenRisks Relating to Our Business Generally

    If we fail to maintain an effective system of disclosure controls and procedures and internal control over our financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired

    Minor phrasing adjustments regarding internal control over financial reporting.

  • 59% rewrittenRisks Relating to Our Business Generally

    We may be adversely affected by natural disasters, pandemics, and other catastrophic events, and by man-made problems such as terrorism, that could disrupt our business operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster

    Expanded disaster recovery to include labor unrest and geopolitical conflicts like regional wars.

  • 52% rewrittenRisks Relating to Our Business Generally

    We may require additional capital to support business growth, and this capital might not be available

    Added regulatory uncertainty and scrutiny to the factors impacting capital availability.

  • 49% rewrittenRisks Relating to Our Fintech Segment

    Our total fintech revenue is substantially dependent on the volume of transactions conducted on our platform. If volume declines, our business, operating results, and financial condition would be adversely affected

    Was: Our total fintech revenue is substantially dependent on the volume of transactions conducted on our platform. If volume declines, our business, operating results, and financial condition would be adversely affected and the price of our Common Stock could decline

  • 47% rewrittenRisks Relating to Our Fintech Segment

    Our intellectual property rights are valuable, and any inability to protect them could adversely affect our business, operating results, and financial condition

  • 46% rewrittenRisks Relating to Ownership of Our Common Stock

    The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation

  • 37% rewrittenRisks Relating to Our Fintech Segment

    The loss of one or more of our key personnel, or our failure to attract and retain other highly qualified personnel in the future, could adversely affect our business, operating results, and financial condition

  • 34% rewrittenRisks Relating to Ownership of Our Common Stock

    If securities or industry analysts do not publish or cease publishing research, or publish inaccurate or unfavorable research, about our business, the price of our Common Stock and its liquidity could decline

  • 30% rewrittenRisks Relating to Our Fintech Segment

    Our culture emphasizes innovation, and if we cannot maintain this culture as we grow, our business, operating results, and financial condition could be adversely affected

    Was: Our culture emphasizes innovation, and if we cannot maintain this culture, our business, operating results, and financial condition could be adversely affected

All 36 risk factors

Headings as the filing states them, in filing order.

Risks Relating to Our Business Generally

  1. 01If our estimates or judgment relating to our critical accounting estimates prove to be incorrect, our operating results could be adversely affected64% rewritten
  2. 02If we fail to maintain an effective system of disclosure controls and procedures and internal control over our financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired63% rewritten
  3. 03Adverse economic conditions and volatility in crypto asset markets could reduce transaction volumes, customer activity, and access to banking and capital, which could adversely affect our businessNew
  4. 04We may require additional capital to support business growth, and this capital might not be available52% rewritten
  5. 05We may be adversely affected by natural disasters, pandemics, and other catastrophic events, and by man-made problems such as terrorism, that could disrupt our business operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster59% rewritten
  6. 06Our operations in multiple foreign jurisdictions expose us to political, regulatory, legal, and currency risks that could adversely affect our businessNew

Risks Relating to Our Fintech Segment

  1. 07Our operating results have and will continue to significantly fluctuate, including due to the highly volatile nature of crypto assets
  2. 08Our total fintech revenue is substantially dependent on the volume of transactions conducted on our platform. If volume declines, our business, operating results, and financial condition would be adversely affected49% rewritten
  3. 09Cyberattacks and security breaches of our platform, or those impacting our customers or third parties, could adversely affect our brand, reputation, business, operating results, and financial condition68% rewritten
  4. 10The loss or destruction of private keys required to access our digital assets or those of our customers could result in permanent, irrecoverable lossNew
  5. 11We are subject to an extensive, highly-evolving, and uncertain regulatory landscape and any adverse changes to, or our failure to comply with, any laws and regulations could adversely affect our brand, reputation, business, operating results, and financial condition76% rewritten
  6. 12The potential classification of certain crypto assets as securities by the SEC or other regulators could materially impact our business operations and require significant restructuringNew
  7. 13Evolving tax treatment of digital assets creates uncertainty in our tax obligations and potential retroactive liabilitiesNew
  8. 14We are exposed to risks from blockchain forks and from the decentralized and open-source nature of blockchain protocols, which could disrupt our platform operations, compromise network integrity, and create uncertainty regarding supported digital assetsNew
  9. 15Our platform is exposed to chargeback, fraud, and unauthorized transaction losses, particularly in connection with our payment card and fiat-linked servicesNew
  10. 16Customer crypto assets held on our platform are not insured by the FDIC or SIPC, and customers could suffer losses in the event of platform failureNew
  11. 17Our banking and financial institution relationships may be disrupted, which could have a material adverse effect on our ability to operateNew
  12. 18Regulatory, investor and market focus on climate-related risks and the environmental impact of digital asset networks may impose additional compliance costs and reputational risks on our businessNew
  13. 19Any significant disruption in our products and services, in our information technology systems, or in any of the blockchain networks we support, could result in a loss of customers or funds and adversely affect our brand, reputation, business, operating results, and financial condition70% rewritten
  14. 20If we fail to retain existing customers or add new customers, or if our customers decrease their level of engagement with our products, services and platform, our business, operating results, and financial condition may be significantly harmed88% rewritten
  15. 21We face intense competition from larger crypto platforms, decentralized networks, traditional financial institutions and payment providers, which could reduce our market share, compress margins and increase customer acquisition costsNew
  16. 22We are subject to risks associated with our compliance and risk management methodsNew
  17. 23We obtain, process, and store a large amount of sensitive personal and financial data and are subject to evolving data privacy, data protection, and information security laws and regulations, and any failure to protect such data or comply with applicable requirements could adversely affect our businessNew
  18. 24Our intellectual property rights are valuable, and any inability to protect them could adversely affect our business, operating results, and financial condition47% rewritten
  19. 25The loss of one or more of our key personnel, or our failure to attract and retain other highly qualified personnel in the future, could adversely affect our business, operating results, and financial condition37% rewritten
  20. 26Our culture emphasizes innovation, and if we cannot maintain this culture as we grow, our business, operating results, and financial condition could be adversely affected30% rewritten
  21. 27Our acquisition of Fortress II Holdings and its Mswipe payment card operations exposes us to integration, compliance, and operational risks specific to the payments industryNew

Risks Relating to Our Biotechnology Segment

  1. 28We may be unable to effectuate the planned formal separation of our biotechnology segment, which could adversely affect our financial condition and strategic objectivesNew
  2. 29Effectuating a formal separation of our biotechnology segment is complex and may divert management’s attention and consume significant resources, which could adversely affect both the biotechnology segment and our remaining operationsNew
  3. 30The biotechnology segment, if formally separated, may be unable to raise sufficient capital to fund its operations and development programs as a standalone entity, which could impair its viability and the value realized by our stockholdersNew
  4. 31If effectuating the formal separation results in Alyea becoming a stand-alone publicly traded entity, it may not qualify for or maintain a listing on a national securities exchange, which could impair the liquidity and value of its securities owned by us or, prospectively, by our stockholdersNew
  5. 32Effectuating the formal separation of the biotechnology segment in a spinoff transaction may have adverse tax consequences for our stockholders and for usNew
  6. 33Unlike currently, following a formal separation of our biotechnology segment, it will operate without our financial support and may face challenges in establishing itself as a fully independent companyNew

Risks Relating to Ownership of Our Common Stock

  1. 34The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation46% rewritten
  2. 35Sales or distribution of substantial amounts of our Common Stock, or the perception that such sales or distributions might occur, could cause the market price of our Common Stock to declineNew
  3. 36If securities or industry analysts do not publish or cease publishing research, or publish inaccurate or unfavorable research, about our business, the price of our Common Stock and its liquidity could decline34% rewritten

Other AI Financial 10-Ks

  • FY2024 10-K risk factors
    41 risks

    Company operates across both volatile crypto fintech markets and early-stage biopharmaceutical development.

    Filed Mar 28, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.